SeaStar Medical Holding Corporation (ICU) Earnings Call Transcript & Summary

November 13, 2025

NASDAQ US Health Care Health Care Equipment and Supplies earnings

Earnings Call Speaker Segments

Jackie Cossmon

executive
#1

Thanks, Marvin. Good afternoon, and I appreciate everyone joining us for SeaStar Medical's Third Quarter 2025 Financial Results Conference Call. This is Jackie Cossmon, speaking on behalf of Wheelhouse Life Science Advisors. Here with me from SeaStar Medical are Eric Schlorff, our Chief Executive Officer; Dr. Kevin Chung, Chief Medical Officer; Tim Varacek, Senior Vice President of Commercial and Business Operations; and Brad Town, our Controller. I want to remind everyone listening that remarks management makes on this call will contain forward-looking statements under the meaning of federal securities laws. Such forward-looking statements carry risks and uncertainties that might make actual results differ materially from any results anticipated; to see a list and description of those risks and uncertainties, please look at SeaStar Medical's filings with the Securities and Exchange Commission. In addition, what is discussed on this conference call includes information accurate only as of the date of the live broadcast, 11/13/2025. Except where the law requires it, SeaStar Medical assumes no obligation to revise or update any statements so they reflect events or circumstances. And now I'd like to hand the call over to Eric.

Eric Schlorff

executive
#2

Thank you, Jackie, and I appreciate everyone being here today. From the start of Q3 onward, we've moved our business forward on multiple fronts, and we think that sets us up nicely for the growth ahead. Three highly ranked children's hospitals have come on board as customers, expanding our base, and we also shared some truly striking survival findings involving the Quell immune therapy when used to treat 21 pediatric patients in a commercial setting. Those noteworthy results, which Kevin will walk through, originated from the SAVE surveillance registry and were presented during the Fifth International Symposium on Acute Kidney Injury in Children, held in the final week of September 2025. Although this registry requirement has slowed how quickly we can bring sites on, the information we have keeps showing the therapy's worth and has proven extremely helpful in getting our target customers to recognize what the Quell immune therapy can do commercially. Turning to Quellimmune revenue, net revenue for the third quarter came in at $183,000. As we've noted before — and this matters — our sales tend to fluctuate somewhat between quarters. Comparing the six months that ended September 30 with the six months that ended March 30, our revenue has risen 45%. With additional sites and fresh data on Quellimmune's commercial use, we feel we're building momentum. In fact, during the first half of Q4, Quellimmune orders have already surpassed the whole of Q3. In short, we expect revenue for the full year 2025 to exceed a million dollars. That gives us a solid base to grow from in 2026, and Tim will outline further steps we've taken on the sales side. During Q3, we also posted our first complete quarter of cost of goods tied to product sales, showing a gross profit margin of 92% — comparable to a branded pharmaceutical product — together with a compelling value proposition for hospital systems looking to save money by using Quellimmune. We think this creates an opportunity to generate cash down the road, which lowers how much cash we must raise to keep operations funded. Now, regarding our work on the neutralized AKI trial, we finished the interim analysis, which lets us see early safety information and signs pointing toward efficacy for our neutralized AKI pivotal study of the selective cytophoretic device, or SCD therapy. We're also still bringing on clinical sites so we can hit the new enrollment goal for that trial. Beyond that, we announced today that the first site is now open for the neutralized CRS clinical trial of SCD therapy, aimed at treating patients who have acute chronic systolic heart failure with cardiorenal syndrome, or CRS, and who are awaiting left ventricular assist device, or LVAD, implantation. It's a modest market, but a highly significant opportunity, since it could show the value of SCD therapy in an indication beyond AKI, reinforcing its wide-ranging uses across many destructive hyperinflammation conditions. To wrap up, we kept up our rigorous push to trim expenses even as we delivered solid performance in operations, and we brought in more than $12 million, which bolsters our balance sheet and gives us a longer financial runway. Before handing things to Tim, let me stress one final point: what truly fuels our drive to broaden access to this therapy — reaching more kids and also adults with comparable conditions triggered by damaging hyperinflammation — is the information we observe and the accounts we receive about Quell immune therapy rescuing the lives of gravely ill pediatric patients who, in the majority of instances, face minimal odds of pulling through. The possibilities in this market are substantial, and we are putting in hard work to deliver our life-saving treatment to patients whose survival prospects from hyperinflammation would otherwise be constrained. With that, I'll pass the call to Tim, who will cover our commercial wins and the opportunities in the market.

Tim Varacek

executive
#3

Appreciate it, Eric, and thank you all for being with us on the SeaStar Medical call for the third quarter. Driving product revenue is what we're after with those 20 new pediatric hospitals, and as more centers come on board, that should give us a predictable revenue stream as we head into 2026 and past that. Right now, 10 commercial pediatric hospitals are active — they've gotten through all their IRB approvals and placed orders — which means four new customers have come in since the third quarter started. We're working hard to grow that figure and anticipate more new sites will join before this year wraps up. Like Eric said, our fourth-quarter product sales over the first six weeks already have us on track for revenue above the third quarter's net revenue; and it's worth noting that we've observed a rise in patients getting Quell immune therapy. Making sure every clinically appropriate patient receives Quellimmune therapy accounts, and keeping sites moving through the Quellimmune adoption process as fast as we can, is where our attention sits for the rest of the year and on into 2026. More specifically, we keep applying the best practices we picked up during the Quellimmune launch to roll out tactics around brand awareness, clinical performance, and patient identification — things like supplemental clinical training, building a speakers bureau, and setting up patient care team forums so ideas get shared and operational obstacles that typically come with new product adoption in hospital systems get overcome. Recent publications have also let us leverage clinical and economic data, including the cost savings model that ran in the Journal of Medical Economics, plus a Real World Data Presentation from our patient registry showing the survival benefit of Quellimmune therapy when it's added to CRRT in pediatric AKI. Importantly, we think the patient population for this therapy is much wider than what's being treated today. Along with growing use in our active accounts, we're trying to clear away obstacles in the adoption process for new target accounts. The high-level path to Quellimmune adoption doesn't change from one hospital system to another, but the way sites move through it can differ, as can how they're organized from a clinical care and administrative standpoint. We keep honing the operational side of Quellimmune adoption and try to make it simpler for the customer. Take this example: ahead of our first meeting with a new system that's interested in Quellimmune, we work hard to pinpoint and bring in key staff like nephrology, critical care, nursing, procurement, research, and plenty of others. That might seem obvious, but often the primary investigator and the advocates championing Quellimmune within their system don't know about all these staff members. Bringing these people together with us in one conference ultimately trims the adoption curve, since we can spot the points people, communicate cross-functional requirements, and assign specific tasks to be done in parallel. It's a symphony at work, with lots of role players. And the positive development here is that these initiatives are starting to show results, and not long ago we managed to bring on a major pediatric facility within just six months. That's still not typical, but it represents meaningful headway. Plus, whatever we gain from this rollout will serve SeaStar Medical in later commercial introductions too. And lastly, now that we have our initial registry data available, we've gone to the FDA asking for an exemption from the required registry. We're quite optimistic the FDA will grant this, and we think they'll be on board with speeding up Quellimmune adoption so that potentially more lives can be saved. Now let's discuss the market. We hold strong hopes for 2026, aiming to serve patients by getting Quellimmune therapy into additional pediatric hospital systems. Our unwavering priority is to bring on new sites as fast as we can, and each additional site reduces the ups and downs in our revenue and eventually builds a steady, dependable revenue flow for our investors and for SeaStar Medical. That's what we're aiming for. We think we'll secure a substantial share of this modest yet vital market, and according to our projections the entire US market stands at roughly $100 million, and even taking a small double-digit percentage of it generates considerable worth for our stockholders and brings in crucial revenue for SeaStar Medical. So with that, I'll hand the presentation over to Kevin Chung, our Chief Medical Officer.

Kevin Chung

executive
#4

Appreciate that, Tim. And thanks to each of you for being on the call. I'm happy to share that momentum keeps building in our neutralized AKI pivotal study. Three more clinical sites have come on board since Q3 began, and we've added 21 patients, which takes total enrollment to 146 against our new goal of 339. For anyone newer to this, neutralized AKI is a randomized controlled trial looking at whether as many as 10 consecutive 24-hour SCD treatments can boost 90-day survival or renal recovery among critically ill acute kidney injury patients who need CRRT. Mortality or dialysis dependence at 90 days serves as the composite primary endpoint. As planned, once we hit the 100 patient mark, we ran a prespecified interim analysis to check safety and verify our statistical powering assumptions. I'm glad to say the independent data safety monitoring board, or DSMB, found SCD therapy to be safe, with no adverse events tied to the device seen in the treatment arm. That matters a great deal in the ICU, where people are frequently critically ill, immune-compromised, and relying on several organ support modalities. Among such fragile patients, even small safety issues can lead to serious clinical outcomes, and they frequently turn into gating factors for regulatory review and clinical adoption. A strong safety record is more than just a checkbox during testing—it's what gives doctors confidence, supports productive conversations with the FDA, and ultimately drives adoption in everyday clinical practice. It's encouraging to see SCD keep delivering that level of safety even in these very challenging situations. As we've shared before, the interim look found that the 20% effect size we'd assumed wasn't showing up at that stage. While there was a definite indication of clinical benefit, it simply wasn't large enough to hit statistical significance with the 200-patient sample originally planned. Consequently, in line with the trial's statistical analysis plan, the DSMB recommended we increase total enrollment to 339 patients, ensuring sufficient power to identify meaningful efficacy. To be clear. According to the DSMB, there was an unmistakable and favorable indication of advantage. Enlarging the number of participants represents a constructive move ahead that rests on evidence and aligns with how we approach disciplined clinical research. Through a larger sample, the trial gains greater statistical strength, which puts us in a position to produce findings that are sturdier, carry more weight, and stand a better chance of earning both regulatory approval and acceptance among clinicians. This amounts to a deliberate adjustment in strategy, and it bolsters how confident we feel that the trial will ultimately succeed. We have not waited to respond to what the DSMB advised; alongside the 17 sites already running, we have started bringing eight additional centers online so that our revised enrollment goal can be reached. Our team is moving quickly and carefully, together with our partners in academia and clinical care. We know how much is riding on this, and we're dedicated to getting enrollment finished by 2026. Now I'd like to discuss our SAVE surveillance registry, which monitors how our Quell immune therapy is used commercially in children who are critically ill. At the most recent Fifth International Symposium on Acute Kidney Injury in Children, we presented encouraging early data from 21 pediatric patients treated in real-world settings for sepsis and life-threatening AKI. In this high-risk population, many of whom received the therapy as a last resort, 76% survived to 60 days and 71% survived to 90 days. As a critical care physician, I find these outcomes remarkable. These kids were at death's door. Although the sample remains limited, the indication is unmistakable. Quellimmune is providing these individuals with a real shot at survival. When these clinical results are combined with data from our earlier clinical trial that we initially filed with the FDA, we now have a total of 43 children with survival exceeding 75%, plainly showing how valuable this therapy is. I'd also like to mention something distinctive about the way we gain knowledge from real-world application of Quellimmune. Each month, we hold a call for Quellimmune users, a gathering that brings together both existing and potential clinical users. In those meetings, we've gone over almost every single patient treated within the SAVE surveillance registry. The accounts people share about our device steadying a desperately ill child, often times turning around acute decompensation, are clinically potent and also profoundly significant to everyone here at SeaStar Medical. Such conversations aren't merely anecdotal. They deliver essential perspectives that enhance our registry information and guide optimal practices. Meanwhile, we keep presenting combined outcomes to the wider pediatric nephrology and critical care communities; these real-world findings are beyond merely encouraging. They bolster both the life-saving promise of our therapy and the purpose that propels our whole company. Finally, I want to call attention to the start of our new neutralized CRS trial, which assesses SCD among patients suffering from chronic systolic heart failure made more complex by cardiorenal syndrome, individuals who cannot receive a heart transplant or even an LVAD, or left ventricular assist device. This single-arm feasibility study is set to enroll 20 patients in that setting, aiming to show gains in renal and cardiac function ahead of any mechanical support procedure. A key distinction in this treatment involves how long SCD is administered compared with the neutralized AKI study. These patients receive treatment on an intermittent basis, as much as six hours each day, for as long as six days. In the neutralized AKI study, patients get treatment without interruption, 24 hours every day, for up to ten days; this matters because it may prove the viability of intermittent therapy as a bridge toward more outpatient environments across a wide spectrum of chronic hyperinflammatory illnesses. Should it succeed, neutralized CRS might clear a path for a distinct marketing submission to the FDA, creating an opportunity for a fresh acute therapeutic approach using a different dosing schedule while laying groundwork for moving into chronic conditions treated in outpatient care. As Eric mentioned previously, this trial fits within our comprehensive plan to extend SCD therapy across multiple indications. Be it AKI, CRS, or something else, we trust our platform can revolutionize results for every patient affected by hyperinflammation. Having said that, I'll now pass things along to Brad Town, who serves as our Controller.

Brad Town

executive
#5

Thanks, Kevin. And I appreciate everyone being here with us today. I'll give you a quick rundown of how we did financially in the third quarter. Just so you know, our Form 10-Q is going to be submitted to the SEC within the next 24 hours, and it will contain a fuller discussion of the company's financial results for the three and nine months ended 09/30/2025. That 10-Q is available at seastarmedical.com, or you can get it at sec.gov. Net revenue from Quellimmune sales came in at roughly $183,000 for 2025, versus $68,000 in 2024. As Eric said, we're already experiencing a pleasant increase in sales through the first six weeks of the fourth quarter. Moving on to gross profit, the Q3 financial statements show a gross profit margin of about 92%, and like Eric pointed out, this marks the first full quarter where cost of goods sold was matched against Quellimmune unit sales; for the three months ended 09/30/2024, we didn't recognize cost of goods sold, since the Quellimmune units that were sold had initially been expensed to research and development at the time of acquisition, which happened before we commercialized Quellimmune, and that's in line with US GAAP. Operating expenses came down to $3.7 million in the third quarter of 2025, down from $4.5 million in 2024. That decrease mostly resulted from lower consulting expenses and personnel costs, though it was partly offset by higher clinical research and development expenses along with greater audit fees. Last of all, net loss for the third quarter totaled approximately $3.5 million, or $0.13 per share, based on roughly 26.4 million weighted average shares outstanding; that's against a net loss of about $4.5 million, or $1.10 per share, on approximately 4.1 million weighted average shares outstanding for the third quarter of 2024. Cash as of 09/30/2025 stood at $13.8 million, versus $1.8 million at December 2024. Over the three months ended 09/30/2025, the company brought in $12.4 million through equity offerings and the exercise of 2.8 million warrants; with that, I'll hand the call back over to Eric.

Eric Schlorff

executive
#6

Thanks, Brad. The purpose of today's call on our Q3 financial results was to give everyone an overview of how far we've come, and to paint a clear picture of why we see substantial opportunities ahead for SeaStar Medical; we feel strongly about our capacity to deliver a therapy that saves lives for critically ill patients who currently have no other option for quieting the cytokine storm brought on by an immune system that's overactive. In the months ahead, our aim is to make sure investors grasp the company's value along with the opportunities that lie before us. With that in mind, we'll be present at several conferences that are coming up, and we'll also be sitting down with investors during the week of the JPMorgan Conference in San Francisco, running from January 12 through the fifteenth; we hope some of you will be there. The opportunities that lie ahead for SeaStar, we believe, are substantial, and we look forward to sharing our future progress. With that, I'll turn it over to the operator to open the call for questions. Operator?

Anthony Vendetti

analyst
#7

Thanks. Yeah, I was hoping to hear where things stand now. It's possible you already covered this and I missed it, but on 09/24 — September 24 — 137 had been enrolled out of what the data safety monitoring board, or review board, now says should be 339, which was raised from 200. That was back in September. So at that point, 137 people were in. Where does that figure stand today? Also, at that time, 16 of the 22 to 25 sites had been activated. What is that count now? And given the September change to the enrollment target, do you think things are progressing the way you anticipated?

Eric Schlorff

executive
#8

Hey. Thanks, Anthony; this is Eric. Go ahead, Kevin.

Kevin Chung

executive
#9

Yes. Hello, Anthony. I appreciate it, Eric. Thank you for asking that. Right now, we have 146 patients who have been enrolled. There are 17 sites that are activated, and as I mentioned not long ago, we're proceeding to activate a minimum of 8 more sites. That brings us to roughly 25 sites. We're also hoping to identify additional sites. The criteria for selection, as you know, are quite strict. What I want are champions who will assume ownership of the trial at their location. Screening isn't simple. Choosing patients and getting them signed up isn't simple. So we require the correct site, with the correct investigators and the correct teams, for success. Regarding our projections, we anticipate that with those 8 extra sites, we will reach the target of 339 by December 2026. We're now taking a variety of steps to accomplish this. We're expanding, for instance, within our existing sites into other ICUs, so we're providing training to other ICUs. Take surgical ICUs as an example, so we can raise the count of patients we're able to screen and thereby capture more patients. That's only one illustration, but there are a number of other adjustments we're implementing to lift our enrollment rate above what we've witnessed during the past few months. So given the historical enrollment rate we've observed, together with the addition of more sites, we're confident we can reach that figure, that updated figure of 339 by December 2026. Does that address your question?

Anthony Vendetti

analyst
#10

Yes. Kevin, that was fantastic. It was exactly the kind of detail I wanted, so that's terrific. From what you're saying, it seems you've already pinpointed, as you mentioned, an additional 8 sites, which would bring the total to 25. But, you know, you'll go past that number provided every one of those requirements you have for a location is satisfied. And should you go beyond those 25, it will give you added assurance that you're able to reach those 339 by December, and perhaps, you know, if you can bring even more sites online, maybe you hit it ahead of December of 2026. Would that be accurate?

Kevin Chung

executive
#11

Yeah. Like I mentioned, we understand what’s on the line here. We understand that the clock is ticking. And we’re eager to finish this study. So we’re monitoring it on a weekly basis and on a monthly basis. And should we fall short of the pace we anticipate, we’ll need more sites. So at this point, going by my projections and the historical data on how many patients we’ve enrolled so far, per site each month, we feel fairly confident that adding eight sites will get us there. Now if it appears that won’t happen, we’ll make further changes. We won’t simply sit around and hope we reach 339; as you’re aware, we’re cleared for as many as 30 sites. So we’ll head in that direction if necessary. But as of now, 25 sites looks like the figure we need to reach our target.

Anthony Vendetti

analyst
#12

All right, that sounds good. And regarding what Eric said about the fresh cardiorenal studies—20 patients, one arm—is that literally just starting today, having only been announced today, meaning it's at a very early stage? Is there anything further you can share? What kind of timeline will that involve? And I realize this represents an entirely new category for you. So perhaps any additional detail on that would be wonderful. Thank you.

Kevin Chung

executive
#13

Alright, thanks Anthony. For this study, our plan is to have a minimum of 5 sites up and running. This is an extremely unique group of individuals. Due to their AKI, along with several other factors, these individuals cannot receive mechanical ventricular assist. So our belief is that we can offer these individuals an opportunity to bridge them to the point where they become eligible for mechanical ventricular assist. As far as the schedule goes, it's not clear how fast enrollment will go. Our hope is to enroll people during the coming 12 months and wrap up within 12 months. But we'll only find out once we're truly underway and understand how quickly screening and enrollment move. Consider, for instance, the total number screened at every site—all the organizations we partner with for neutralized CRS are also neutralized AKI sites. Since these are different patients, there's no competition between them for this specific study. Still, our projection is that we ought to complete enrolling 20 patients inside of 12 months. That could change, of course, if, say, site activation gets delayed. Screening has been underway for a few weeks now; we've identified a few strong candidates, though they simply weren't enrolled. But once all 5 sites are activated—and we'll be announcing them individually—we ought to reach our goal inside of 12 months. 5 sites, and as you can see, that isn't many patients per site.

Anthony Vendetti

analyst
#14

Alright, that's useful. And now for my final question, directed at Eric. I believe I caught you saying near the start of this call — and of course, we're aware that at this point revenue can be somewhat volatile and somewhat uneven. But was it that you stated we're on track to hit roughly a million, or beyond a million, across the whole of '25? Allow me to clear that up.

Eric Schlorff

executive
#15

Thanks, Anthony. Right, that matches what we stated — we were on track to hit over a million during this year.

Anthony Vendetti

analyst
#16

Okay. Great. Thanks so much. Appreciate it. I'll hop back in the queue.

Jackie Cossmon

executive
#17

Thanks, Marvin. I appreciate everyone being here for SeaStar Medical's call on our financial results for the third quarter. Should you have any questions, reach out to us at ircstarmed.com, or you can go to our site, www.seastarmedical.com. Thanks so much, and farewell.

Operator

operator
#18

We appreciate everyone for joining us on this call. That brings the program to an end. You are free to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete SeaStar Medical Holding Corporation transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to SeaStar Medical Holding Corporation earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in SeaStar Medical Holding Corporation or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.